CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function

Bone Marrow Transplantation

Volumn 45, Issue 10, 2010, Pages 1489-1496

  Jing, D ^a   Oelschlaegel, U ^a   Ordemann, R ^a   Holig K ^a   Ehninger, G ^a,b   Reichmann, H ^a,b   Ziemssen, T ^a   Bornhauser M ^a,b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

G CSF; hematopoietic stem and progenitor cells; migration; mobilization; natalizumab

Indexed keywords

ALPHA4 INTEGRIN; CD133 ANTIGEN; CD34 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CXCR4; GELATINASE B; GRANULOCYTE COLONY STIMULATING FACTOR; MESSENGER RNA; NATALIZUMAB; PROTEIN P21;

ADULT; ARTICLE; BONE MARROW CELL; CELL ACTIVITY; CELL COUNT; CELL FUNCTION; CELL MIGRATION; CELL SUBPOPULATION; CELLULAR DISTRIBUTION; CLONOGENESIS; CONTROLLED STUDY; ERYTHROID PRECURSOR CELL; FEMALE; GENE EXPRESSION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD STEM CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEADY STATE; STEM CELL EXPANSION; STEM CELL MOBILIZATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD34; BONE MARROW CELLS; CELL MOVEMENT; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ERYTHROID PRECURSOR CELLS; FEMALE; GLYCOPROTEINS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HOMEOSTASIS; HUMANS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; INTEGRIN ALPHA4; MALE; MATRIX METALLOPROTEINASE 9; MULTIPLE SCLEROSIS; PEPTIDES; RNA, MESSENGER;

EID: 77957947043     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.381     Document Type: Article

References (27)

1. Copelan EA. Hematopoietic stem-cell transplantation. New Engl J Med 2006; 354: 1813-1826.
2. Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-644.
3. Schmitz N, Dreger P, Suttorp M, Rohwedder EB, Haferlach T, Loffler H et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-1672.
4. Lane TA, Law P, Maruyama M, Young D, Burgess J, Mullen M et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995; 85: 275-282.
5. Roberts AW, DeLuca E, Begley CG, Basser R, Grigg AP, Metcalf D. Broad inter-individual variations in circulating progenitor cell numbers induced by granulocyte colony-stimulating factor therapy. Stem Cells 1995; 13: 512-516.
6. Moncada V, Bolan C, Yau YY, Leitman SF. Analysis of PBPC cell yields during large-volume leukapheresis of subjects with a poor mobilization response to filgrastim. Transfusion 2003; 43: 495-501.
7. Dipersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for auto-logous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-5726.
8. Papayannopoulou T, Nakamoto B. Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin. Proc Natl Acad Sci USA 1993; 90: 9374-9378.
9. Craddock CF, Nakamoto B, Andrews RG, Priestley GV, Papayannopoulou T. Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice. Blood 1997; 90: 4779-4788.
10. Wenning W, Haghikia A, Laubenberger J, Clifford DB, Behrens PF, Chan A et al. Treatment ofprogressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 2009; 361: 1075-1080.
11. Linda H, von HA, Major EO, Ryschkewitsch C, Berg J, Olsson T et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 2009; 361: 1081-1087.
12. Zohren F, Toutzaris D, Klarner V, Hartung HP, Kieseier B, Haas R. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 2008; 111: 3893-3895.
13. Bonig H, Wundes A, Chang KH, Lucas S, Papayannopoulou T. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 2008; 111: 3439-3441.
14. Vuaillat C, Androdias G, Davoust N, Nataf S. About multiple sclerosis, natalizumab, and CD34+ hematopoietic progeni-tors. Blood 2008; 112: 208-209.
15. Forsberg EC, Smith-Berdan S. Parsing the niche code: the molecular mechanisms governing hematopoietic stem cell adhe-sion and differentiation. Haematologica 2009; 94: 1477-1481.
16. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006; 25: 977-988.
17. Nie Y, Han YC, Zou YR. CXCR4 is required for the quiescence of primitive hematopoietic cells. J Exp Med 2008; 205: 777-783.
18. Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 2006; 6: 93-106.
19. Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003; 111: 187-196.
20. Watanabe T, Dave B, Heimann DG, Lethaby E, Kessinger A, Talmadge JE. GM-CSF-mobilized peripheral blood CD34+ cells differ from steady-state bone marrow CD34+ cells in adhesion molecule expression. Bone Marrow Transplant 1997; 19: 1175-1181.
21. Christopher MJ, Liu F, Hilton MJ, Long F, Link DC Suppression of CXCL12 production by bone marrow osteo-blasts is a common and critical pathway for cytokine-induced mobilization. Blood 2009; 114: 1331-1339.
22. Janowska-Wieczorek A, Marquez LA, Nabholtz JM, Cabuhat ML, Montano J, Chang H et al. Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane. Blood 1999; 93: 3379-3390.
23. Fukuda S, Bian H, King AG, Pelus LM. The chemokine GRObeta mobilizes early hematopoietic stem cells character-ized by enhanced homing and engraftment. Blood 2007; 110: 860-869.
24. Fargeas CA, Corbeil D, Huttner WB. AC133 antigen, CD133, prominin-1, prominin-2, etc.: prominin family gene products in need of a rational nomenclature. Stem Cells 2003; 21: 506-508.
25. Hess DA, Wirthlin L, Craft TP, Herrbrich PE, Hohm SA, Lahey R et al. Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood 2006; 107: 2162-2169.
26. Freund D, Oswald J, Feldmann S, Ehninger G, Corbeil D, Bornhauser M. Comparative analysis ofproliferative potential and clonogenicity of MACS-immunomagnetic isolated CD34+ and CD133+ blood stem cells derived from a single donor. Cell Prolif 2006; 39: 325-332.
27. Ramirez P, Rettig MP, Uy GL, Deych E, Holt MS, Ritchey JK et al. BIO5192, a small molecule inhibitor ofVLA-4, mobilizes hematopoietic stem and progenitor cells. Blood 2009; 114: 1340-1343.